WO1994008613A3 - Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse - Google Patents

Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse Download PDF

Info

Publication number
WO1994008613A3
WO1994008613A3 PCT/EP1993/002755 EP9302755W WO9408613A3 WO 1994008613 A3 WO1994008613 A3 WO 1994008613A3 EP 9302755 W EP9302755 W EP 9302755W WO 9408613 A3 WO9408613 A3 WO 9408613A3
Authority
WO
WIPO (PCT)
Prior art keywords
parathormone
pregnancy
treatment
biologically active
active fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1993/002755
Other languages
English (en)
Other versions
WO1994008613A2 (fr
Inventor
Franco Bagnoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/411,726 priority Critical patent/US5880093A/en
Priority to JP6509588A priority patent/JPH08502271A/ja
Priority to EP93922531A priority patent/EP0663835B1/fr
Priority to AU51499/93A priority patent/AU680631B2/en
Priority to KR1019950701350A priority patent/KR100293846B1/ko
Priority to DE69310528T priority patent/DE69310528T2/de
Application filed by Individual filed Critical Individual
Publication of WO1994008613A2 publication Critical patent/WO1994008613A2/fr
Publication of WO1994008613A3 publication Critical patent/WO1994008613A3/fr
Priority to NO19951050A priority patent/NO317930B1/no
Anticipated expiration legal-status Critical
Priority to GR970401802T priority patent/GR3024157T3/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compositions pharmaceutiques contenant, comme principe actif, la parathormone, ses fragments à activité biologique et des peptides associés (PTHrP), éventuellement en combinaison avec des adjuvants appropriés et pharmaceutiquement acceptables. Ces compositions sont utilisées pour la prévention et le traitement de l'avortement et de naissances prématurées, et en général pour le traitement de problèmes liés à la grossesse.
PCT/EP1993/002755 1992-10-09 1993-10-08 Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse Ceased WO1994008613A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP6509588A JPH08502271A (ja) 1992-10-09 1993-10-08 パラトルモン、その生物学的活性フラグメント及び関連ペプチドの妊娠時の治療への使用
EP93922531A EP0663835B1 (fr) 1992-10-09 1993-10-08 Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse
AU51499/93A AU680631B2 (en) 1992-10-09 1993-10-08 Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy
KR1019950701350A KR100293846B1 (ko) 1992-10-09 1993-10-08 임신치료를위한파라소먼,그생물학적활성프래그먼트및관련펩티드의용도
DE69310528T DE69310528T2 (de) 1992-10-09 1993-10-08 Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
US08/411,726 US5880093A (en) 1992-10-09 1993-10-08 Use of parathormone, its biologically active fragments and correlated peptides, for the preparation of pharmaceutical compositions useful for the treatment of pregnancy
NO19951050A NO317930B1 (no) 1992-10-09 1995-03-20 Anvendelse av paratyroidhormon, dets biologisk aktive fragmenter og korrelerte peptider for fremstilling av farmasoytiske blandinger for behandling under svangerskap.
GR970401802T GR3024157T3 (en) 1992-10-09 1997-07-17 Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI922331A IT1255723B (it) 1992-10-09 1992-10-09 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
ITMI92A002331 1992-10-09

Publications (2)

Publication Number Publication Date
WO1994008613A2 WO1994008613A2 (fr) 1994-04-28
WO1994008613A3 true WO1994008613A3 (fr) 1994-05-26

Family

ID=11364090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/002755 Ceased WO1994008613A2 (fr) 1992-10-09 1993-10-08 Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse

Country Status (14)

Country Link
US (1) US5880093A (fr)
EP (1) EP0663835B1 (fr)
JP (1) JPH08502271A (fr)
KR (1) KR100293846B1 (fr)
AT (1) ATE152628T1 (fr)
AU (1) AU680631B2 (fr)
CA (1) CA2146666A1 (fr)
DE (1) DE69310528T2 (fr)
DK (1) DK0663835T3 (fr)
ES (1) ES2103493T3 (fr)
GR (1) GR3024157T3 (fr)
IT (1) IT1255723B (fr)
NZ (1) NZ256679A (fr)
WO (1) WO1994008613A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
AU691725B2 (en) * 1995-02-20 1998-05-21 Masahiro Iwamoto Therapeutics of osteoarthritis and inflammatory joint disease
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6043981A (en) * 1997-11-13 2000-03-28 Chrysler Corporation Heat sink assembly for electrical components
ZA9811127B (en) † 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
WO2000023594A1 (fr) * 1998-10-22 2000-04-27 The General Hospital Corporation PEPTIDES ET DERIVES PEPTIDIQUES BIOACTIFS DE L'HORMONE PARATHYROIDE (PTH) ET DE LA PROTEINE LIEE A L'HORMONE PARATHYROIDE (PTHrP)
WO2001023521A2 (fr) * 1999-09-29 2001-04-05 The General Hospital Corporation Derives polypeptidiques de l'hormone parathyroidienne (pth)
WO2003009804A2 (fr) * 2001-07-23 2003-02-06 The General Hospital Corporation Analogues d'hormone parathyroide (pth) a contrainte conformationnelle
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
WO2004067021A1 (fr) * 2003-01-24 2004-08-12 Gardella Thomas J Analogues de parathormone (pth) a contrainte conformationnelle avec ponts lactame
WO2004093902A1 (fr) * 2003-03-19 2004-11-04 The General Hospital Corporation Hormones parathyroidiennes contraintes de maniere conformationnelle avec des stabilisateurs en helice $g(a)
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
EP1767541A4 (fr) * 2004-05-26 2008-10-22 Greenpeptide Co Ltd Peptide a liaison hla-a24 ou hla-a2 de proteine lie a la parathormone
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
CN101784281B (zh) 2007-08-01 2014-07-02 总医院有限公司 确定g蛋白偶联受体激动剂的方法
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
L.L.S. MOK ET AL.: "Parathyroid Hormone as a Smooth Muscle Relaxant", ENDOCRINE REVIEWS, vol. 10, no. 4, November 1989 (1989-11-01), pages 420 - 436 *
R.L. SHEW ET AL.: "Uterine Relaxing Action of Parathyroid Hormone: Effect of Oxidation and Methionine Substitution", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 175, no. 4, April 1984 (1984-04-01), pages 444 - 448 *

Also Published As

Publication number Publication date
AU5149993A (en) 1994-05-09
NZ256679A (en) 1997-03-24
GR3024157T3 (en) 1997-10-31
CA2146666A1 (fr) 1994-04-28
ATE152628T1 (de) 1997-05-15
ITMI922331A1 (it) 1994-04-09
EP0663835A1 (fr) 1995-07-26
ES2103493T3 (es) 1997-09-16
DE69310528T2 (de) 1997-09-11
AU680631B2 (en) 1997-08-07
US5880093A (en) 1999-03-09
WO1994008613A2 (fr) 1994-04-28
JPH08502271A (ja) 1996-03-12
KR950703359A (ko) 1995-09-20
DE69310528D1 (de) 1997-06-12
ITMI922331A0 (it) 1992-10-09
EP0663835B1 (fr) 1997-05-07
DK0663835T3 (da) 1997-09-01
KR100293846B1 (ko) 2001-09-17
IT1255723B (it) 1995-11-13

Similar Documents

Publication Publication Date Title
EP0663835A1 (fr) Utilisation de parathormone, de ses fragments a activite biologique et de peptides associes pour le traitement de problemes de grossesse.
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
ZA944347B (en) The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
CA2189250A1 (fr) Agents regulateurs des cytokines et leurs procedes d'utilisation dans des affections et etats pathologiques associes a des taux de cytokines modifies
CA2319201A1 (fr) Compositions a base de celecoxib
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
CA2373794A1 (fr) Compositions et utilisation d'et743 pour le traitement du cancer
CA2139385A1 (fr) Produits renfermant une proteine liante de g-csf et de tnf
AU1890295A (en) Piperidines and pyrrolidines
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO1996022305A3 (fr) Peptides modifies
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
EP0821969A3 (fr) Composition médicale contenant du TCF-II
CA2361081A1 (fr) Traitement de la sclerose en plaques a la chaperonine 10 et au .beta.-interferon
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
AU7941294A (en) Composition for the treatment or prevention of herpes
IL110289A0 (en) Pharmaceutical compositions comprising 4'-iodo-4'- deoxydoxorubicin for treating amyloidosis
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
CA2157590A1 (fr) Utilisation de la terbinafine pour le traitement de la pneumocystose
AU6037494A (en) Use of active substances in the therapy of certain diseases, process for preparing a pharmaceutical composition for that purpose and pharmaceutical compositions thus prepared

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MN MW NO NZ PL RO RU SD SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08411726

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2146666

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019950701350

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1993922531

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 256679

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1993922531

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993922531

Country of ref document: EP